coin-img-ETHETH+2.23%coin-img-BTCBTC+2.07%coin-img-SOLSOL+2.50%coin-img-USDCUSDC-0.01%coin-img-UBOXUBOX-71.40%coin-img-XRPXRP+1.60%coin-img-HYPEHYPE+3.08%coin-img-BNBBNB+4.67%coin-img-ETHETH+2.23%coin-img-BTCBTC+2.07%coin-img-SOLSOL+2.50%coin-img-USDCUSDC-0.01%coin-img-UBOXUBOX-71.40%coin-img-XRPXRP+1.60%coin-img-HYPEHYPE+3.08%coin-img-BNBBNB+4.67%coin-img-ETHETH+2.23%coin-img-BTCBTC+2.07%coin-img-SOLSOL+2.50%coin-img-USDCUSDC-0.01%coin-img-UBOXUBOX-71.40%coin-img-XRPXRP+1.60%coin-img-HYPEHYPE+3.08%coin-img-BNBBNB+4.67%coin-img-ETHETH+2.23%coin-img-BTCBTC+2.07%coin-img-SOLSOL+2.50%coin-img-USDCUSDC-0.01%coin-img-UBOXUBOX-71.40%coin-img-XRPXRP+1.60%coin-img-HYPEHYPE+3.08%coin-img-BNBBNB+4.67%
user-avatar
Benzinga

Alnylam cuts 2026 TTR sales outlook as second-line Amvuttra demand normalizes; shares drop 29.27%

AI Market Summary
Alnylam's Q2 beat on adjusted EPS was outweighed by a revenue miss and a cut to 2026 TTR product sales guidance as second-line ATTR-CM demand normalized after earlier pent-up uptake. The guidance reduction, alongside heightened sensitivity around ATTR-CM development timelines, triggered a sharp drawdown in ALNY, signaling deteriorating near-term sentiment toward the name and potentially pressuring risk appetite across similar biotech launch stories.
Impact level
● Medium
Affected assets
NCCOGOLD2USD/USDT+1.04%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Alnylam Pharmaceuticals posted second-quarter 2024 results with adjusted EPS of $1.84, above expectations, while revenue came in at $1.291 billion, slightly below forecasts. Amvuttra generated $1,012 million in quarterly revenue, and Onpattro contributed $18 million. The company trimmed its full-year 2026 TTR product sales guidance, saying second-line demand in the ATTR-CM market has normalized after pent-up demand was met. ALNY shares fell 29.27% on the day.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.